Pancragen
Also known as: KEDW, Lys-Glu-Asp-Trp, Lys-Glu-Asp-Trp-NH₂, KEDW-NH₂, Pancragene
4 notable studies · 4 references
TLDR
Pancragen is the synthetic tetrapeptide Lys-Glu-Asp-Trp (KEDW), with direct pancreatic-cell, diabetic-rat, and aged-rhesus-monkey evidence suggesting effects on pancreatic differentiation, glucose handling, and insulin/C-peptide responses, but human clinical evidence remains extremely limited and the findings have not been independently replicated enough to establish it as a treatment for diabetes or pancreatic dysfunction.
Research Supports
- Studied for effects on pancreatic-cell differentiation in aging human embryonic pancreatic-cell cultures
- Investigated for effects on glucose regulation in experimental diabetic rats
- Studied for age-related pancreatic endocrine function in aged rhesus monkeys
- Investigated for microvascular effects in diabetic animal models
- Explored via molecular modeling for potential direct DNA-binding activity
Observations Reported in Research
- Increased expression of CXCL12 and HOXA3 in aging human pancreatic-cell cultures, more strongly in older cultures (Khavinson et al., 2012)
- Produced a pronounced glucose-lowering effect in streptozotocin-diabetic rats and normalized abnormal capillary adhesion but not permeability (Khavinson et al., 2007)
- Normalized abnormal insulin/C-peptide response to glucose challenge in old rhesus monkeys, with some effects persisting three weeks after treatment (Goncharova et al., 2014)
- Molecular modeling proposed GGCAG as a potential KEDW-DNA binding sequence, a mechanistic hypothesis only (Tarnovskaya et al., 2014)
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic tetrapeptide; insulinotropic-peptide mimetic; experimental pancreatic/endocrine bioregulator
Pancragen is a four-amino-acid peptide: Lys-Glu-Asp-Trp (KEDW) with several of the original experiments specifically studying the C-terminally amidated form, Lys-Glu-Asp-Trp-NH₂. That distinction should be retained because research-market products do not always specify which form they contain. Unlike several organ-named bioregulators, Pancragen's pancreatic association has meaningful direct experimental support. It has been studied in pancreatic cells, experimental diabetic rats, aged rhesus monkeys, and molecular models of DNA interaction. In old rhesus monkeys, Pancragen altered glucose disappearance and normalized the abnormal insulin/C-peptide response to glucose challenge, with some effects reportedly persisting three weeks after treatment ended. But nearly all of this work comes from the same Khavinson research lineage, and there is still no strong independently replicated randomized human clinical evidence.
What Is Pancragen?
Pancragen is somewhat different from the simple “extract → identify short sequence → synthesize peptide” story attached to several bioregulators. The originating literature describes KEDW as a mimetic of a short motif occurring in insulinotropic peptides. Subsequent experiments investigated whether the tetrapeptide could influence pancreatic-cell differentiation and glucose regulation. That gives Pancragen a more concrete biological hypothesis: KEDW → pancreatic-cell signaling/gene regulation → endocrine pancreatic function → insulin/glucose response. That chain has experimental support through the pancreatic-cell and animal stages. The final step—clinically meaningful treatment of human diabetes—has not been established.
What Are Researchers Studying?
Pancreatic cell differentiation
Researchers studied aging cultures of human embryonic pancreatic cells and measured differentiation-related factors. Pancragen increased expression of CXCL12 and HOXA3, with the effect reported as stronger in older/late-passage cultures. Importantly, the same experiment found tissue-associated responses to different short peptides. That provides substantially better support for Pancragen's pancreatic association than simply calling it a “pancreas peptide.”
Pancreatic cell differentiation
Researchers studied aging cultures of human embryonic pancreatic cells and measured differentiation-related factors. Pancragen increased expression of CXCL12 and HOXA3, with the effect reported as stronger in older/late-passage cultures. Importantly, the same experiment found tissue-associated responses to different short peptides. That provides substantially better support for Pancragen's pancreatic association than simply calling it a “pancreas peptide.”
Glucose regulation
In Wistar rats with streptozotocin-induced experimental diabetes, Pancragen produced a pronounced reduction in blood glucose during treatment. The study also examined microvascular effects. Intramuscular Pancragen normalized adhesion of mesenteric capillary endothelium but did not significantly alter capillary permeability. That's a useful mixed result rather than a universally positive one.
Age-related pancreatic endocrine function
This is probably Pancragen's most interesting experiment. Researchers compared glucose responses in young and old female rhesus monkeys. Older animals displayed slower glucose disappearance, higher insulin peaks, and higher C-peptide peaks after glucose challenge. Following Pancragen exposure, researchers reported faster glucose disappearance and normalization of insulin and C-peptide dynamics. Some effects remained detectable three weeks after discontinuation. Because rhesus monkeys are much closer physiologically to humans than rodents, this is meaningful preclinical evidence. It's still not a human diabetes trial.
Insulin resistance
Pancragen's animal research has investigated glucose tolerance and insulin responses rather than merely measuring pancreatic morphology. That makes metabolic regulation one of its more defensible research areas. However, experimental improvement in glucose handling in old monkeys or diabetic rats does not establish treatment of type 1 diabetes, type 2 diabetes, prediabetes, or metabolic syndrome in humans.
Microvascular dysfunction
Diabetes affects vascular biology as well as glucose metabolism. The rat study therefore examined capillary adhesion and permeability. Pancragen normalized abnormal endothelial adhesion but did not correct capillary permeability, suggesting selective rather than universal vascular effects.
Gene regulation
Molecular-modeling research examined whether KEDW could interact directly with DNA. Researchers proposed GGCAG as a potential binding sequence and found modeled interactions involving both major and minor DNA grooves. This remains a mechanistic hypothesis. Molecular modeling ≠ demonstrated intracellular DNA binding in living humans.
How Does It Work?
There isn't an established conventional Pancragen receptor. The working experimental model is approximately: Pancragen / KEDW → cellular uptake → changes in pancreatic differentiation-associated gene expression → altered pancreatic endocrine-cell behavior → changes in insulin/C-peptide response → changes in glucose handling. Direct human pancreatic-cell experiments support the middle portion of that chain, while animal experiments support the physiological portion. A proposed direct DNA-binding mechanism remains substantially less certain.
What Does the Research Show?
Human research
Human-derived cells: YES. Pancragen has been studied directly in cultured human embryonic pancreatic cells. Human administration: VERY LIMITED / LOW-CERTAINTY. A small Russian report involving roughly three dozen older people with type 2 diabetes is described in later evidence reviews, but it was uncontrolled and has not been independently replicated. There is no modern randomized Pancragen diabetes trial. Human clinical evidence: VERY LOW rather than none.
Animal research
MODERATE for an experimental bioregulator. The evidence includes streptozotocin-diabetic rats, aging rhesus monkeys, glucose-tolerance experiments, insulin/C-peptide measurements, and microvascular endpoints. The weakness isn't absence of animal evidence. It's lack of independent replication.
In-vitro research
MODERATE. Pancragen has direct pancreatic-cell evidence involving differentiation markers. That makes the pancreas association substantially more defensible than several other organ-specific peptide labels examined.
Notable Studies
Effect of Pancragen on Blood Glucose Level, Capillary Permeability and Adhesion in Rats with Experimental Diabetes Mellitus
animalAnimal — streptozotocin-induced diabetes. Pancragen was studied in Wistar rats with experimental diabetes. Oral exposure produced a marked glucose-lowering effect during treatment, while intramuscular exposure normalized abnormal mesenteric endothelial adhesion but did not alter capillary permeability.
Limitations: Experimental rodent diabetes differs from human diabetes; small research lineage; no independent replication establishing clinical relevance.
View publication →Peptides Tissue-Specifically Stimulate Cell Differentiation During Their Aging
in-vitroIn vitro — human pancreatic cells. Researchers studied differentiation markers in aging cultures of human embryonic pancreatic and bronchial cells and human prostatic fibroblasts. Pancragen increased pancreatic-cell expression of CXCL12 and HOXA3, with stronger effects in aging cultures.
Limitations: Cell culture rather than administration to humans. Changes in differentiation markers don't establish improved pancreatic function or diabetes outcomes.
View publication →Impact of Tetrapeptide Pancragen on Endocrine Function of the Pancreas in Old Monkeys
animalAnimal — aged rhesus monkeys. Researchers assessed glucose, insulin and C-peptide responses in old female rhesus monkeys. Pancragen increased glucose disappearance and normalized abnormal insulin/C-peptide dynamics after glucose challenge; part of the reported effect persisted three weeks after exposure ended.
Limitations: Small nonhuman-primate study from the originating research network; no demonstration of reduced diabetic complications or durable clinical benefit.
View publication →Study of Interactions Between DNA and Tetrapeptides Using Methods of Molecular Mechanics
in-vitroSource evidence type was Computational / molecular modeling; closest dropdown match is In-vitro. Molecular modeling examined interactions between KEDW and DNA and proposed GGCAG as a potential sequence-specific binding site.
Limitations: Computational interaction modeling does not establish nuclear uptake, DNA occupancy, transcriptional regulation or therapeutic effects in living organisms.
View publication →What We Still Don't Know
Human pharmacokinetics; Human half-life; Oral bioavailability; Whether free-acid KEDW and amidated KEDW-NH₂ behave equivalently; Long-term human safety; Whether it meaningfully lowers HbA1c; Whether it prevents diabetic complications; Whether it changes β-cell mass; Whether it preserves β-cell function; Whether effects persist long term; Whether direct DNA binding occurs in vivo; Whether results replicate outside the originating research network.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Pancragen research with you.
Get the Aminodex Pancragen Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Khavinson VKh, Gavrisheva NA, Malinin VV, et al. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. Bull Exp Biol Med. 2007.
- Khavinson VKh, Linkova NS, Polyakova VO, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012.
- Goncharova ND, Ivanova LG, Oganian TÉ, et al. Impact of tetrapeptide Pancragen on endocrine function of the pancreas in old monkeys. Adv Gerontol. 2014.
- Tarnovskaya SI, Yakutseni PP, Khavinson VKh. Study of interactions between DNA and tetrapeptides using methods of molecular mechanics. Bull Exp Biol Med. 2014.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.